Introduction
============

Hypertension and aortic stenosis result in chronic pressure-overload of the left ventricle, producing left ventricular hypertrophy, and are considered risk factors for the development of heart failure ([@B20]). Prolonged pressure-overload has also been shown to cause structural and functional adaptations in the coronary vasculature. Coronary flow reserve is decreased and minimal coronary resistance is increased ([@B12]; [@B15]; [@B13]), due to increased extravascular compression of the arterioles, decreased capillary density and vascular remodeling ([@B6]; [@B40]; [@B3]; [@B15]; [@B42]; [@B41]). Functional changes in the coronary vasculature mainly result from an increase in oxidative stress and endothelial dysfunction ([@B34]; [@B21]; [@B1]) resulting in an imbalance between endothelium-derived vasodilators such as Nitric Oxide (NO) and prostacyclin and endothelium-derived vasoconstrictors like endothelin and reactive oxygen species ([@B44]).

Uridine adenosine tetraphosphate (Up4A) was initially identified as an endothelium-derived vasoconstrictor. A role for Up~4~A in the pathogenesis of hypertension has been suggested by the observation that Up~4~A-induced vascular contraction in the renal, femoral and basilar artery is potentiated in hypertension ([@B28]). In addition, the Up~4~A plasma concentration in hypertensive subjects is significantly higher as compared to healthy subjects and positively correlates with blood pressure ([@B16]). Up~4~A contains both purine and pyrimidine moieties and, like other extracellular nucleotides, exerts its vasoactive influence by binding to purinergic receptors ([@B27]; [@B47]), a class of receptors comprising P1 (adenosine receptors) and P2 receptors, that can be further subdivided into P2X and P2Y subtypes ([@B32]). Subsequent studies found that the vasoactive effect of Up~4~A is not only dependent on the vascular bed but also on the species studied. Thus, Up~4~A produces potent relaxation in the healthy porcine coronary vasculature ([@B47]) whereas vasoconstriction is observed in response to Up~4~A in the murine coronary microcirculation ([@B39]). Interestingly, Up~4~A-induced relaxation is attenuated in the remote coronary vasculature after myocardial infarction via downregulation of P1 receptors ([@B46]). Although Up~4~A-induced coronary relaxation is maintained in swine with metabolic derangement, the purinergic signaling and endothelium-derived factors involved in Up~4~A responses are markedly altered ([@B49]). Altogether, these findings indicate that the effects of Up~4~A in the porcine coronary vasculature change in cardiovascular disease.

Consequently, the first aim of the present study was to investigate whether prolonged pressure overload induced by AoB alters the response to Up~4~A in isolated porcine coronary small arteries, and to determine the purinergic receptors and endothelium-derived factors mediating this altered vascular response to Up~4~A. Interestingly, we found evidence for release of a vasoconstrictor prostanoid in response to Up~4~A in AoB. As the vasoconstrictor prostanoid thromboxane A~2~ (TxA~2~) was recently shown to be released in response to Up~4~A in renal arteries and aortas ([@B29]; [@B50]), we further investigated whether Up~4~A can induce production of TxA~2~ in the porcine coronary microvasculature.

Materials and Methods {#s1}
=====================

Animals
-------

Studies were performed in accordance with the "Guiding Principles in the Care and Use of Laboratory Animals" as approved by the Council of the American Physiological Society, and with approval of the Animal Care Committee at Erasmus Medical Center Rotterdam. Fifteen Crossbred Yorkshire X Landrace swine (2 to 3-month-old, 18.5 ± 0.3 kg at the time of surgery) of either sex entered the study. Swine were housed in the animal facility in cages with a 12/12 h light/dark cycle, *ad libitum* access to water and were fed twice per day. After 1 week of daily adaptation to laboratory conditions, animals underwent either AoB (*n* = 7) or a sham procedure (Sham; *n* = 8).

Surgery
-------

After overnight fasting, swine were sedated with an intramuscular injection of Zoletil (Tiletamine/Zolazepam; 5 mg kg^-1^), Xylazine (2.25 mg kg^-1^), and Atropine (1 mg), and a small catheter was placed in an earvein for subsequent administration of fluid. Swine were intubated and ventilated with a mixture of oxygen and nitrogen (1:2 vol/vol), to which 2% (vol/vol) isoflurane was added to maintain anesthesia ([@B14]; [@B18]). Under sterile conditions, the chest was opened via the fourth left intercostal space and fluid-filled polyvinylchloride catheters were inserted into the left ventricle (LV), only in AoB swine, and in the aortic arch (Ao) of both Sham and AoB swine, for the measurement of the pressure and blood sampling for the determination of PO~2~, PCO~2~, pH, O~2~ saturation, and hemoglobin concentration. The ascending aorta was exposed in all swine, a sterile plastic band was placed around the ascending aorta in AoB animals and gradually tightened until the systolic pressure gradient between distal aorta and proximal LV catheters reached approximately 80 mmHg. Then, the chest was closed and animals were allowed to recover, receiving analgesia (0.3 mg buprenorphine i.m.) for 2 days and antibiotic prophylaxis (25 mg kg^-1^ amoxicillin and 5 mg kg^-1^ gentamycin i.v.) for 5 days. Pressure in the proximal and distal catheters were recorded at the time of surgery, as well as 1 and 3 weeks after surgery, and the systolic pressure gradient was calculated. Due to malfunctioning of the catheters in a number of animals, pressures could not be obtained 8 weeks after the initial surgery.

Eight weeks after initial Sham and AoB surgery, animals were re-anesthetized, intubated and ventilated as described above. Pentobarbital (20 mg kg^-1^ h^-1^) was infused to induce and maintain anesthesia. A catheter was introduced via the femoral artery into the descending aorta for measurement of mean arterial pressure. A Swan Ganz catheter was inserted via the jugular vein and advanced into the pulmonary artery for measurement of PAP and CO (via thermodilution) ([@B43]). Following thoracotomy, hearts were arrested and immediately excised and placed in cold, oxygenated Krebs bicarbonate buffer solution.

Myograph Studies
----------------

Coronary small arteries (diameter: ∼150 μm) were dissected out from the apex of eight Sham-operated and seven AoB swine and stored overnight in cold, oxygenated Krebs bicarbonate solution of the following composition (mM): NaCl 118, KCl 4.7, CaCl~2~ 2.5, MgSO~4~ 1.2, KH~2~PO~4~ 1.2, NaHCO~3~ 25, and glucose 8.3; pH 7.4. The next day, coronary small arteries were cut into segments of ∼2 mm length and mounted in microvascular myographs (Danish Myo Technology) with separated organ baths containing 6 ml Krebs bicarbonate solution aerated with 95%O~2~/5%CO~2~ and maintained at 37°C ([@B4]; [@B47], [@B49]). Changes in contractile force were recorded with a Harvard isometric transducer. Following a 30 min stabilization period, the internal diameter was set to a tension equivalent to 0.9 times the estimated diameter at 100 mmHg effective transmural pressure ([@B4]; [@B47], [@B49]). At the end of the stabilization period, the vessels were exposed to 30 mM KCl twice to check the contractility. Endothelial integrity was verified by observing dilation to 10 nM substance P after preconstriction with 100 nM of the stable TxA~2~ analog U46619. Then vessels were subjected to 100 mM KCl to determine maximal vascular contraction. Thereafter, vessels were allowed to equilibrate in fresh organ bath fluid for 30 min before initiating different experimental protocols ([@B4]; [@B47]). In experiments where the effect of an antagonist on the response to Up~4~A was assessed, antagonists were added to the organ baths 30 min before preconstriction with U46619 and were present throughout the experiments. Only one protocol was executed per vessel and, within one protocol, all vessels were obtained from different animals.

Experimental Protocols
----------------------

Coronary small arteries from both Sham and AoB swine were subjected to Up~4~A in incremental concentrations ranging from 10^-9^ to 10^-5^ M in the absence and presence of preconstriction with U46619 ([@B47]). To assess the involvement of different purinergic receptors in the vasodilator response to Up~4~A, coronary small arteries from Sham and AoB swine were pre-incubated with non-selective P1 receptor antagonist 8PT (10^-5^ M), non-selective P2 receptor antagonist PPADS (10^-5^ M), adenosine A~2A~ receptor antagonist SCH58261 (10^-8^ M), P2X~1~ receptor antagonist MRS2159 (3 × 10^-5^ M), and P2Y~1~ receptor antagonist MRS2179 (10^-6^ M) followed by preconstriction with U46619 (100 nM) ([@B47]) and exposed to Up~4~A (10^-9^ to 10^-5^ M). To investigate if the role of endothelium-derived factors in the vasodilator response to Up~4~A was altered after AoB, vessels from both Sham and AoB were exposed to Up~4~A (10^-9^ to 10^-5^ M) in the absence and presence of nitric oxide synthase (NOS) inhibitor LNAME (10^-4^ M) alone or in combination with cyclooxygenase (COX) inhibitor indomethacin (10^-5^ M) ([@B47]). A potential role for TxA~2~ in the response to Up~4~A was assessed using coronary small arteries from porcine hearts (*n* = 5) obtained from a local slaughterhouse. The response to Up~4~A of coronary small arteries of slaughterhouse pigs was similar to that of Sham-operated pigs (**Figure [2](#F2){ref-type="fig"}**). A subset of these vessels was de-endothelialized to mimic endothelial dysfunction of cardiovascular disease condition and exposed to the TxS inhibitor ozagrel (10^-5^ M), the P2Y~12~ receptor antagonist clopidogrel (10^-6^ M), that can be converted to its active metabolites by cytochrome P450 enzymes shown to be present in the heart ([@B9]; [@B36]) or a combination of ozagrel and clopidogrel prior to exposure to Up~4~A.

Histology
---------

Fresh sections of anterior wall of the left ventricle were fixed by 4% buffered formaldehyde and paraffin-embedded for histological analysis of remodeling of coronary small arteries. Sections were stained with resorcin-fuchsin as an elastin stain, photographed and inner and outer area of the coronary small arteries was assessed by planimetry ([@B38]). Only transversely cut vessels with an inner radius below 200 μm were analyzed. Assuming circularity of the vessels, inner and outer radius were calculated as r = √(area/π). Wall to lumen ratio was calculated as (outer--inner diameter)/inner diameter.

Quantitative Real-Time PCR Analysis
-----------------------------------

Following dissection, coronary small arteries (diameter: ∼150 μm) were snap-frozen in liquid nitrogen to be used for detection of purinergic receptor subtypes A~1~, A~2A~, A~3~, P2X~1~, P2X~4~, P2X~7~, P2Y~1~, P2Y~2~, P2Y~4~, P2Y~6~, and P2Y~12~ mRNA. In addition, the expression of endothelial NOS (eNOS), cyclooxygenase (COX) 1, COX2, prostacyclin synthase (PGIS), and TxS were measured ([@B35]). Total RNA was extracted from 5 to 7 frozen samples per group using a Qiagen RNA kit. cDNA was synthesized from 100 ng of total RNA with iScript Reverse Transcriptase (Bio-Rad). Quantitative real-time PCR (MyIQ, Bio-Rad) was performed with SYBR Green (Bio-Rad) ([@B47]). Target gene mRNA levels were expressed relative to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an endogenous control ([@B25]). The primer sequences are shown in **Table [1](#T1){ref-type="table"}**.

###### 

Primer information.

  Receptors   Sequence                      Size (bp)                     
  ----------- ----------------------------- ----------------------------- -----
  A~1~        5′-CCTGGCCATGCTGGCAATTGC-3′   5′-GAAGGAGAGAACCCAGCAGCC-3′   251
  A~2A~       5′-ATGTTGGGCTGGAATAGCTG-3′    5′-CACGGAGTTGGTGTGAGAGA-3′    426
  A~3~        5′-TACCTGCGGGTCAAGCTCACG-3′   5′-CCAGGAATGACACCAGCCAGC-3′   97
  P2X~1~      5′-TTGAACCCCATTTCTTCCTG-3′    5′-AGTGCACCACACATCTGCTC-3′    248
  P2X~4~      5′-TGTCCCCAGGCTACAATTTC-3′    5′-GGCAGCTTTTTCTCCCTTCT-3′    373
  P2X~7~      5′-CTTTTGCACCTTGAGCTTCC-3′    5′-TCCATGCTAAGGGATTCTGG-3′    152
  P2Y1        5′-TTCCTGACTTGCATCAGTGC-3′    5′-CAGTGCCCGAGTAGAAGAGG-3′    157
  P2Y~2~      5′-GTGGCCTACAGCTTGGTCAT-3′    5′-GCGTGCGGAAGGAGTAGTAG-3′    235
  P2Y~4~      5′-GACTGCCGGTTTAATGAGGA-3′    5′-AGGAAAAGGACGCTGCAGTA-3′    302
  P2Y~6~      5′-CTGCTCTTGCCACCTGTGTA-3′    5′-AGGTTGGCGTAGAACAGGAA-3′    251
  P2Y~12~     5′-AGTGATGCCAAACTGGGAAC-3′    5′-TGAATGCCCAGATAACCACA-3′    208
  COX1        5′-GGAGTTTGTCAATGCCACCT-3′    5′-GCAACTGCTTCTTCCCTTTG-3′    215
  COX2        5′-GGCTGCGGGAACATAATAGA-3′    5′-GCAGCTCTGGGTCAAACTTC-3′    183
  PGIS        5′-CATGCGTGCTCTGATTCACT-3′    5′-AAGCTGATGCAAAGGCAAGT-3′    233
  TxS         5′-AGCAAGCAGCAGAAGAGAGG-3′    5′-TCAGAGGCTTGGACAGAGGT-3′    180
  eNOS        5′-CTCTCCTGTTGGCCTGACCA-3′    5′-CCGGTTACTCAGACCCAAGG-3′    151
  GAPDH       5′-TCGGAGTGAACGGATTTG-3′      5′-CCTGGAAGATGGTGATGG-3′      219
                                                                          

Data Analysis and Statistics
----------------------------

Hemodynamic data were averaged over a time period of at least 10 s. Vascular contractions were normalized to the response to 100 mM KCl, while vascular relaxation to Up~4~A was expressed as percentage of contraction to U46619 ([@B47]). Statistical comparison of hemodynamic data, purinergic receptor expression, vascular response to KCl and comparison of wall to lumen ratio of vessels \< 200 μm between Sham and AoB swine were performed using unpaired *t*-tests. The effect of AoB on wall to lumen ratio was analyzed with ANCOVA, using inner or outer radius as covariant. The effects of AoB as well as drug treatment on the Up~4~A response were assessed using two-way ANOVA for repeated measures. Statistical significance was accepted when *P* \< 0.05 (two-tailed). Data are presented as means ± SEM.

Results
=======

Characteristics of AoB Animals
------------------------------

Aortic banding of the ascending aorta resulted in a systolic pressure gradient of 88 ± 2 mmHg as measured during surgery (**Table [2](#T2){ref-type="table"}**). The systolic pressure gradient was stable over the time course of the experiment, as evidenced by a systolic pressure gradient of 82 ± 8 and 98 ± 6 mmHg at week 1 and week 3 after AoB (**Table [2](#T2){ref-type="table"}**). Mean arterial pressure distal to the band was lower in AoB as compared to Sham during surgery and 1 week after surgery, but was similar to mean arterial pressure in Sham-operated swine 3 weeks after surgery. At end of follow-up, the HR, mean arterial pressure, and CO were comparable between Sham and AoB swine, while the PAP was slightly increased in AoB (**Table [2](#T2){ref-type="table"}**). Eight weeks of AoB resulted in left ventricular hypertrophy as evidenced by a 56% increase in left ventricle weight to BW ratio (**Table [2](#T2){ref-type="table"}**). The wall to lumen ratio of coronary small arteries was also increased (**Figures [1A,B](#F1){ref-type="fig"}** for typical examples, **Figures [1C,D](#F1){ref-type="fig"}** for all results, **Figure [1F](#F1){ref-type="fig"}** for vessels with an inner diameter ranging from 100 to 200 μm) and the vascular response to 100 mM KCl in the coronary small arteries from AoB was significantly greater as compared to that from Sham (**Figure [1E](#F1){ref-type="fig"}**). These observations indicate that during 8 weeks of AoB, swine develop left ventricular hypertrophy as well as medial hypertrophy of the coronary microvessels.

###### 

Anatomic and hemodynamic variables.

                                       Sham        AoB
  -------------------------- --------- ----------- -------------
  MAP (mmHg)                 Surgery   84 ± 6      56 ± 3\*
                             Week 1    92 ± 2      83 ± 2\*
                             Week 3    88 ± 2      90 ± 3
  LVSP (mmHg)                Surgery   --          155 ± 5
                             Week 1    --          176 ± 8
                             Week 3    --          188 ± 14
  SAP (mmHg)                 Surgery   99 ± 6      67 ± 4\*
                             Week 1    112 ± 2     100 ± 2\*
                             Week 3    105 ± 2     104 ± 3
  Pressure gradient (mmHg)   Surgery   --          88 ± 2
                             Week 1    --          82 ± 8
                             Week 3    --          98 ± 6
  **At end of follow-up**                          
  BW (kg)                              45 ± 0.9    42 ± 1.1
  LVW/BW (g kg^-1^)                    2.3 ± 0.1   3.6 ± 0.1\*
  HR (beats min^-1^)                   109 ± 3     108 ± 4
  MAP (mmHg)                           98 ± 5      104 ± 3
  CO (L min^-1^)                       4.0 ± 0.2   4.2 ± 0.1
  PAP (mmHg)                           19 ± 1      23 ± 1\*
                                                   

AoB, aortic banding; MAP, mean arterial pressure measured in the descending aorta; LVSP, left ventricular systolic pressure measured proximal to the band; SAP, systolic artery pressure measured in the descending aorta; BW, body weight; LVW, left ventricular weight; HR, heart rate; CO, cardiac output; PAP, pulmonary arterial pressure. Those values were obtained under anesthesia at the end of follow-up. Values are mean ± SEM;

∗

P

\< 0.05 vs. Sham.

![Typical examples of coronary small arteries within the myocardium of Sham-operated swine **(A)** and swine with AoB **(B)**. The scale bar denotes 100 μm. The wall to lumen ratio both as a function of inner **(C)** and outer **(D)** was significantly increased in myocardium from swine with AoB. Shown are 34 vessels from 4 Sham-operated swine and 36 vessels from 5 AoB swine. The vasoconstrictor response to 100 mM KCl was significantly increased in vessels from AoB (*n* = 6) as compared to Sham (*n* = 8), **(E)**. The wall to lumen ratio in vessels with inner diameters ranging from 100 to 200 μm was increased in AoB as compared to Sham **(F)**. ^∗^*P* \< 0.05 AoB vs. Sham.](fphar-09-00255-g001){#F1}

Up~4~A-Induced Coronary Relaxation Is Blunted in AoB
----------------------------------------------------

Cumulative concentrations of Up~4~A (10^-9^ to 10^-5^ M) failed to induce vascular contraction in coronary small arteries from either Sham or AoB swine. The vasoconstrictor effect of U46619 (normalized to 100 mM KCl) was not significantly different between Sham and AoB (89 ± 15 vs. 61 ± 9%, *P* = 0.16). In these preconstricted vessels, Up~4~A produced concentration-dependent relaxation, but the relaxation was significantly less in vessels from AoB as compared to Sham (**Figure [2](#F2){ref-type="fig"}**).

![Reduced vasodilator responses to Up~4~A in coronary small arteries from swine with AoB (*n* = 6) as compared to Sham-operated (*n* = 8) or Slaughterhouse (*n* = 5) swine. ^∗^*P* \< 0.05 AoB vs. Sham or Slaughterhouse.](fphar-09-00255-g002){#F2}

Involvement of Purinergic Receptor Subtypes
-------------------------------------------

Despite unaltered expression of the A~1~, A~2A~, and A~3~ receptor (**Figure [3](#F3){ref-type="fig"}**), P1 receptor blockade with 8PT attenuated Up~4~A-induced relaxation in coronary small arteries from AoB more than in Sham (**Figures [4A,B](#F4){ref-type="fig"}**). Conversely, A~2A~ receptor blockade with SCH58261 attenuated Up~4~A-induced relaxation to the same extent as 8PT in coronary small arteries from Sham, but had no effect on Up~4~A-induced relaxation in AoB (**Figures [4A,B](#F4){ref-type="fig"}**). Non-selective P2 receptor blockade with PPADS had no effect on Up~4~A-induced relaxation in coronary small arteries from Sham (**Figure [5A](#F5){ref-type="fig"}**), but did attenuate Up~4~A-induced relaxation in vessels from AoB (**Figure [5B](#F5){ref-type="fig"}**). P2X~1~ receptor blockade with MRS2159 attenuated Up~4~A-induced relaxation in coronary small arteries from Sham (**Figure [6A](#F6){ref-type="fig"}**) and AoB swine (**Figure [6B](#F6){ref-type="fig"}**) to a similar extent, whereas P2Y~1~ receptor blockade with MRS2179 attenuated Up~4~A-induced relaxation in coronary small arteries from Sham (**Figure [6C](#F6){ref-type="fig"}**), but not AoB swine (**Figure [6D](#F6){ref-type="fig"}**). P2X~1~, P2X~7~, P2Y~1~, P2Y~2~ and P2Y~6~ receptors were expressed, but no differences in expression in coronary small arteries between Sham and AoB were found (**Figure [3](#F3){ref-type="fig"}**). Expression of P2Y~12~ receptors was higher in coronary small arteries from AoB (**Figure [3](#F3){ref-type="fig"}**), while expression of P2X~4~ and P2Y~4~ could not be detected (data not shown).

![mRNA expression of various P receptor subtypes in coronary small arteries from Sham-operated swine and swine with AoB. mRNA expression was normalized to expression of GAPDH. ^∗^*P* \< 0.05 vs. Sham.](fphar-09-00255-g003){#F3}

![P1 receptor blockade with 8PT attenuated relaxation to Up~4~A less in coronary small arteries from Sham-operated swine (**A**, *n* = 6) as compared to coronary small arteries from swine with AoB (**B**, *n* = 6). A~2A~ receptor blockade with SCH58261 attenuated Up~4~A-induced relaxation in coronary small arteries from Sham (*n* = 5), but not AoB (*n* = 5). Control data are the same as in **Figure [2](#F2){ref-type="fig"}** ('Sham' and 'AoB'). ^∗^*P* \< 0.05 effect of 8PT vs. corresponding control. ^†^*P* \< 0.05 effect of 8PT vs. corresponding SCH58261.](fphar-09-00255-g004){#F4}

![P2 receptor blockade with PPADS had no effect on relaxation to Up~4~A in coronary small arteries from Sham-operated swine (**A**, *n* = 8) but attenuated relaxation in coronary small arteries from swine with AoB (**B**, *n* = 7). Control data are the same as in **Figure [2](#F2){ref-type="fig"}** ('Sham' and 'AoB'). ^∗^*P* \< 0.05 effect of PPADS vs. corresponding control.](fphar-09-00255-g005){#F5}

![P2X~1~ receptor blockade with MRS2159 attenuated relaxation to Up~4~A to the same extent in coronary small arteries from Sham-operated swine (**A**, *n* = 8) and from swine with AoB (**B**, *n* = 6), whereas and P2Y~1~ receptor blockade with MRS2179 attenuated relaxation to Up~4~A in coronary small arteries from Sham-operated swine (**C**, *n* = 7) but not from swine with AoB (**D**, *n* = 5). Control data are the same as in **Figure [2](#F2){ref-type="fig"}** ('Sham' and 'AoB').^∗^*P* \< 0.05 effect of MRS2159 or MRS2179 vs. corresponding control.](fphar-09-00255-g006){#F6}

Involvement of Endothelium-Derived Factors in the Response to Up~4~A
--------------------------------------------------------------------

To investigate the contribution of alterations in endothelial function to the attenuated response to Up~4~A after AoB, the effects of eNOS and COX inhibition on Up~4~A-induced relaxation were assessed. eNOS inhibition with LNAME attenuated Up~4~A-induced relaxation to the same extent in coronary small arteries from Sham and AoB swine (**Figures [7A,B](#F7){ref-type="fig"}**), which was corroborated by similar eNOS expression level in vessels from AoB and Sham (**Figure [8](#F8){ref-type="fig"}**).

![eNOS inhibition with LNAME attenuated the response to Up~4~A to a similar extent in coronary small arteries from Sham-operated swine (**A**, *n* = 8) and swine with AoB (**B**, *n* = 7). Subsequent inhibition of cyclooxygenase with indomethacin (Indo) had no effect in vessels from Sham (**C**, *n* = 7), but enhanced relaxation to Up~4~A in vessels from swine with AoB (**D**, *n* = 6). Control data are the same as in **Figure [2](#F2){ref-type="fig"}** ('Sham' and 'AoB'). ^∗^*P* \< 0.05 effect of LNAME vs. corresponding control; ^†^*P* \< 0.05 effect of LNAME + indomethacin vs. LNAME alone.](fphar-09-00255-g007){#F7}

![mRNA expression of eNOS, cyclooxygenase (COX) 1 and COX2, prostacycline synthase (PGIS) and TxS in coronary small arteries from Sham-operated swine and swine with AoB. mRNA expression was normalized to expression of GAPDH.](fphar-09-00255-g008){#F8}

In Sham-operated swine, combined inhibition of eNOS and COX (LNAME+indomethacin) attenuated Up~4~A-induced relaxation to the same extent as LNAME alone (**Figure [7C](#F7){ref-type="fig"}**). In contrast, combined inhibition of eNOS and COX in vessels from AoB swine significantly enhanced Up~4~A-induced relaxation compared to LNAME alone (**Figure [7D](#F7){ref-type="fig"}**), although COX1, COX2, and PGIS expression were not different in coronary small arteries between Sham and AoB (**Figure [8](#F8){ref-type="fig"}**). The observation that COX-inhibition enhanced the vasodilator effect of Up~4~A suggests the production of a vasoconstrictor prostanoid(s). There is some evidence linking TxA~2~ production to P2Y~12~ receptor activation ([@B5]). Given the increased P2Y~12~ receptor expression in coronary small arteries of AoB (**Figure [3](#F3){ref-type="fig"}**), we further investigated if TxA~2~ could be the vasoconstrictor prostanoid produced in response to Up~4~A, as well as the functional involvement of P2Y~12~ receptor in this process. Coronary small arteries were denuded to mimic endothelial dysfunction in hypertension. Subsequently, endothelium-intact and -denuded vessels were exposed to Up~4~A in the presence of the TxS inhibitor ozagrel, the P2Y~12~ receptor antagonist clopidogrel or their combination. Ozagrel had no effect on the response to Up~4~A in coronary small arteries with intact endothelium (**Figure [9A](#F9){ref-type="fig"}**), but enhanced the vasodilator response to Up~4~A in denuded coronary small arteries (**Figure [9B](#F9){ref-type="fig"}**). Similarly, clopidogrel enhanced the vasodilator response to Up~4~A in denuded coronary small arteries (**Figure [9B](#F9){ref-type="fig"}**), but not in coronary small arteries with intact endothelium (**Figure [9A](#F9){ref-type="fig"}**). As the effect of the combination of ozagrel and clopidogrel was identical to the effect of either ozagrel or clopidogrel alone (**Figure [9B](#F9){ref-type="fig"}**), these data are consistent with the concept that P2Y~12~ receptor activation may induce TxA~2~ production.

![Neither TxS inhibition with ozagrel, nor P2Y~12~ receptor blockade with clopidogrel (Clop), nor the combination affected the response to Up~4~A in coronary small arteries from slaughterhouse swine with intact endothelium (**A**, *n* = 5). Ozagrel and clopidogrel enhanced vasodilator response to Up~4~A in denuded coronary small arteries, while the effect of the combination of ozagrel and clopidogrel was similar to the effect of either inhibitor alone (**B**, *n* = 5). Control data are the same as in **Figure [2](#F2){ref-type="fig"}** 'Slaughterhouse.' ^∗^*P* \< 0.05 effect of denudation; †*P* \< 0.05 effect of ozagrel and/or clopidogrel vs. corresponding control.](fphar-09-00255-g009){#F9}

Discussion
==========

The main findings of the present study were that (i) AoB resulted in medial hypertrophy of coronary small arteries as evidenced by an increase in wall-to-lumen ratio and an increased KCl-induced contractile force. (ii) Up~4~A-induced relaxation was reduced in coronary small arteries from AoB as compared to Sham. (iii) Blockade of P1 receptors attenuated Up~4~A-induced relaxation less in coronary small arteries from Sham as compared to AoB, but the contribution of the A~2A~ receptor was reduced. (iv) P2 receptor blockade with PPADS attenuated Up~4~A-induced relaxation in AoB but not Sham. (v) The response to P2X~1~ blockade was similar in coronary small arteries from AoB and Sham. (vi) P2Y~1~ receptor blockade attenuated Up~4~A-induced relaxation in Sham, but not AoB. (vii) Expression of the P2Y~12~ receptor was increased in coronary small arteries from AoB, while expression of other purinergic receptor subtypes involved in vascular tone regulation was not altered. (viii) eNOS inhibition attenuated Up~4~A-induced relaxation to the same extent in Sham and AoB, whereas additional COX inhibition had no effect in Sham, but enhanced Up~4~A-induced relaxation in AoB. (ix) P2Y~12~ receptor blockade and/or TxS inhibition enhanced the vasodilator response to Up~4~A in denuded coronary small arteries. The implications of these findings are discussed below.

Consistent with previous reports ([@B11]; [@B2]), 8 weeks of AoB resulted in left ventricular hypertrophy and coronary microvascular remodeling, as evidenced by doubling of wall to lumen ratio of the coronary small arteries and doubling of the contractile response to KCl. The vasodilator response to Up~4~A was blunted in coronary small arteries from swine with AoB. Up~4~A exerts its vasoactive effect through interaction with purinergic receptors. In accordance with previous studies from our laboratory ([@B47]), coronary relaxation induced by Up~4~A in swine was mediated primarily by the P1 receptors. Although the expression of the A~1~, A~2A~, and A~3~ receptors was unaltered after AoB, the overall contribution of the P1 receptors to Up~4~A-induced vasorelaxation was increased, while contribution of the A~2A~ receptor was reduced. These findings are different from our findings in the porcine coronary vasculature after MI ([@B46]) and metabolic derangement ([@B49]), in which the reduced response to Up~4~A was not due to functional loss of A~2A~ receptors. Although studies in mice ([@B48]) and swine ([@B22]) showed that the main vasoactive effect of adenosine was mediated through A~2A~, rather than A~2*B*~ receptor, we cannot exclude that altered expression of the A~2*B*~ receptor could explain the increased contribution of P1 receptors to the vasorelaxation to Up~4~A in coronary small arteries from AoB as compared to Sham.

The assessment of the contribution of the P2 receptors to the response to Up~4~A is difficult due to lack of selective antagonists of many of the P2 receptor subtypes. In general, activation of P2 receptors on endothelial cells is thought to result in vasodilation, whereas activation of P2 receptors on vascular smooth muscle cells results in vasoconstriction ([@B26]; [@B8]; [@B47]). The non-selective P2 antagonist PPADS attenuated Up~4~A-induced relaxation in coronary small arteries from swine with AoB, but not from Sham-operated swine, indicating that the contribution of P2 receptors blocked by PPADS is altered. PPADS has been shown to block P2X~2~, P2X~3~, P2X~5~ ([@B7]), P2X~7~ ([@B30]), P2Y~1~ ([@B17]), P2Y~2~, P2Y~4~ ([@B33]), and P2Y~6~ ([@B37]) receptors. In contrast to the altered effect of PPADS, blockade of P2X~1~ receptors attenuated the vasodilator response to Up~4~A to the same extent in coronary small arteries from AoB and Sham-operated swine, which is in accordance with its unaltered expression. Conversely, despite unaltered expression of the P2Y~1~ receptor, its vasodilator effect in response to Up~4~A that was present in coronary small arteries from Sham disappeared after AoB. The observation that, in vessels from Sham-operated swine, P2Y~1~ blockade attenuated the response to Up~4~A, whereas PPADS, that has also been shown to block the P2Y~1~ receptor, does not, suggests that PPADS also blocks a P2 vasoconstrictor receptor. The exact identity of this receptor remains to be elucidated. Interestingly, expression of the P2Y~12~ receptor was increased in coronary small arteries from swine with AoB. As activation of the P2Y~12~ receptor on vascular smooth muscle cells results in vasoconstriction ([@B45]), increased expression of this receptor could explain the reduced vasodilator effect of Up~4~A in coronary small arteries from swine with AoB. A role for the P2Y~12~ receptor in the reduced vasodilator response to Up~4~A is further substantiated by our observation that P2Y~12~ blockade with clodipogrel enhanced the vasodilator response to Up~4~A in denuded vessels, although it had no effect on the vasodilator response in vessels with intact endothelium. Altogether, our data indicate that Up~4~A-mediated activation of the P2Y~12~ receptor on the vascular smooth muscle cells results in vascular contraction, while the presence of healthy endothelium prevents such response.

Since several studies have shown endothelial dysfunction in the porcine coronary vasculature following AoB ([@B23],[@B24]; [@B11]; [@B2]), we further investigated whether the contribution of endothelial vasodilator pathways to Up~4~A-induced relaxation was altered. The blunted response to Up~4~A was not due to a decreased contribution of NO, as both the effect of eNOS-inhibition with LNAME and eNOS expression were similar in coronary small arteries from Sham-operated swine and swine with AoB. The unaltered expression of eNOS is consistent with another study in isolated coronary arteries from swine with AoB ([@B24]). Also, the contribution of eNOS to bradykinin-induced relaxation was maintained ([@B2]), despite the presence of eNOS uncoupling ([@B24]).

Cyclooxygenase-inhibition with indomethacin potentiated the vasodilator response to Up~4~A in vessels from AoB, but not Sham-operated animals, suggesting that the reduced responsiveness to Up~4~A was, at least in part, due to production of a vasoconstrictor prostanoid(s). A shift in the balance from vasodilator prostanoids to vasoconstrictor prostanoids has been implicated in the pathogenesis of cardiovascular disease ([@B19]). A potential mechanism behind such shift may be that oxidative stress and/or endothelial dysfunction result in eNOS uncoupling, which subsequently leads to the production of peroxynitrite, that is capable of inactivating PGIS thereby causing a shift in production from prostacyclin to TxA~2~ ([@B51]; [@B31]). Indeed, TxA~2~ levels were increased in the myocardium of hypercholesterolemic swine with endothelial dysfunction ([@B10]). Furthermore, the presence of a healthy endothelium in the present study prevented production of TxA~2~, as inhibition of TxS with ozagrel enhanced the vasodilator response to Up~4~A in denuded coronary small arteries, but not in those with intact endothelium. A link between the vasoconstrictor effect of Up~4~A and TxA~2~ production is further supported by a recent study demonstrating that Up~4~A stimulates TxA~2~ production leading to vascular contraction in mouse aortas ([@B50]). Moreover, an enhanced contraction in response to Up~4~A is mediated through activation of COX2 and production of TxA~2~ in the renal vasculature of diabetic rats ([@B29]). Although mRNA levels of COX1, COX2, PGIS, and TxS were unaltered in coronary small arteries from swine with AoB in the present study, it is possible that the *activity* of COX2 and/or TxS was increased following stimulation with Up~4~A. Preliminary data from coronary small arteries from two swine with AoB show that inhibition of TxS with ozagrel after LNAME has a similar effect as indomethacin, suggesting that indeed, TxS activity is increased. An increased production of TxA~2~ in the coronary vasculature in AoB is not unique to Up~4~A, but has also been shown in response to bradykinin and serotonin ([@B11]). It is unlikely that the response of the coronary microvasculature to TxA~2~ receptor activation was altered, as the response to the TxA~2~ analog U46619 was identical in vessels from Sham and AoB swine.

There is some evidence linking TxA~2~ production to activation of the P2Y~12~ receptor. Thus, TxA~2~ levels were reduced in human serum treated with P2Y~12~ inhibitors, P2Y~12~ inhibition reduced serum TxA~2~ in mice, and serum TxA~2~ levels were reduced in P2Y~12~ knockout mice ([@B5]). Consistent with these observations, in the present study, P2Y~12~ blockade enhanced the vasodilator response to Up~4~A to a similar extent as TxS inhibition, and combined inhibition of P2Y~12~ receptor and TxS had no additional effect as compared to each treatment alone.

A role for Up~4~A in the pathogenesis of hypertension has been suggested by the observation that Up~4~A-induced vascular contraction in the renal, femoral, and basilar artery is potentiated in hypertension ([@B28]), while the Up~4~A plasma concentration in hypertensive subjects is significantly higher as compared to that in healthy subjects and correlates with blood pressure ([@B16]). The present study shows that pressure overload-induced coronary vascular remodeling results in attenuation of the vasodilator effect of Up~4~A, which is accompanied by increased expression of P2Y~12~ receptor. Activation of the P2Y~12~ receptor on vascular smooth muscle likely results in activation of TxS and TxA~2~ production in response to Up~4~A, thereby blunting its vasodilator effect in the coronary microcirculation. Future experiments are required to investigate if indeed the P2Y~12~ receptor is a key factor in activation of TxS in AoB animals, as well as the signal transduction pathway involved.
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AoB

:   aortic banding

BW

:   body weight

CO

:   cardiac output

HR

:   heart rate

LNAME

:   N^ω^-nitro-[L]{.smallcaps}-arginine methyl ester HCl

LVSP

:   left ventricular systolic pressure measured proximal to the band

LVW

:   left ventricular weight at end of follow-up

MAP

:   mean arterial pressure measured in the descending aorta

NO

:   nitric oxide

PAP

:   pulmonary arterial pressure

PGI2

:   prostacyclin

PGI2S

:   prostacyclin synthase

PPADS

:   pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid

P1-receptors

:   purinergic type 1 receptors

P2-receptors

:   purinergic type 2 receptors

SAP

:   systolic artery pressure measured in the descending aorta

TxS

:   thromboxane synthase

Up~4~A

:   uridine adenosine tetraphosphate

U46619

:   9,11-dideoxy-9α,11α-methanoepoxy Prostaglandin F2α

8PT

:   8-phenyltheophylline
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